Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

Interim Phase 1 Data Evaluating MOv18 IgE, an Anti-folate Receptor Alpha IgE antibody, in Cancer Patients with Advanced Solid Tumours to be Presented at the AACR Virtual Annual Meeting I

MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer  London, 20 April 2020 – Epsilogen (formerly IGEM Therapeutics), a global leader in the development of immunoglobulin E (IgE) antibodies to…